BioAge Labs Provides Business Updates

Key Takeaways

• BGE-102 cut hsCRP 86% in obese participants.
• IL‑1β suppression reached 90‑98% at Day 14.
• Phase 2a cardiovascular trial slated early 2026.
• DME eye trial to start mid‑2026.
• $132.3M follow‑on offering funds operations through 2029.

Summary

BioAge Labs reported full‑year 2025 results, highlighting positive Phase 1 data for its oral NLRP3 inhibitor BGE‑102, which achieved up to 86% reduction in hsCRP and strong suppression of IL‑1β, IL‑6, and fibrinogen. The company announced a Phase 2a cardiovascular risk trial for early 2026 and an ophthalmology proof‑of‑concept study in diabetic macular edema slated for mid‑2026. It also advanced its APJ agonist program toward an IND filing by year‑end 2026. An upsized $132.3 million follow‑on offering extends BioAge’s cash runway through 2029.

Pulse Analysis

BioAge’s interim Phase 1 results for BGE‑102 mark a notable advance in oral NLRP3 inhibition, a pathway traditionally dominated by injectable agents. By delivering 86% median hsCRP reduction and near‑complete IL‑1β suppression, the compound demonstrates best‑in‑class anti‑inflammatory potency that could translate into a convenient, once‑daily pill for patients at elevated cardiovascular risk. This biomarker profile, coupled with cerebrospinal fluid exposure exceeding the IC90, differentiates BGE‑102 from peers and sets the stage for a dose‑ranging Phase 2a trial aimed at a potential Phase 3 registration by late 2027.

Beyond cardiovascular indications, BioAge is leveraging the inflammasome’s role in retinal disease to expand BGE‑102 into ophthalmology, targeting diabetic macular edema (DME). Preclinical data show near‑complete protection against vascular leakage, supporting a Phase 1b/2a proof‑of‑concept study planned for mid‑2026. Simultaneously, the company’s APJ agonist pipeline—bolstered by a nanobody partnership with JiKang Therapeutics and a pending IND—adds therapeutic breadth, addressing metabolic and vascular disorders linked to aging biology. Strategic collaborations with Novartis and Lilly further enrich target discovery and antibody development capabilities.

Financially, the $132.3 million upsized follow‑on offering, combined with $285.1 million in cash and marketable securities, extends BioAge’s operational runway to 2029, providing a stable platform for multiple concurrent trials. This capital strength reduces dilution risk and signals investor confidence in the company’s aging‑focused drug discovery model. As the biotech sector seeks scalable, oral therapies for chronic inflammation, BioAge’s integrated pipeline and robust financing could position it as a key player in the emerging market for age‑related disease therapeutics.